Introduction Sotorasib is an oral targeted anticancer drug marketed under the brand name Lumakras. Pharmacologically, sotorasib is a KRAS G12C inhibitor and belongs to the class of RAS GTPase inhibitors. KRAS is an important intracellular signaling protein involved in cell growth, proliferation, differentiation, survival, and apoptosis regulation. Normally, KRAS works like a molecular switch. It … Read more
Introduction Axitinib is an oral targeted anticancer drug marketed under the brand name Inlyta. Pharmacologically, axitinib is a receptor tyrosine kinase inhibitor that mainly blocks vascular endothelial growth factor receptors, also called VEGFRs. Renal cell carcinoma is a highly vascular tumor, meaning it depends strongly on blood vessel formation for growth and spread. Tumor cells … Read more
Introduction Amivantamab is a targeted anticancer monoclonal antibody used in selected patients with non-small cell lung cancer, commonly abbreviated as NSCLC. It is marketed under the brand name Rybrevant as intravenous amivantamab-vmjw. A subcutaneous formulation, Rybrevant Faspro, contains amivantamab with hyaluronidase-lpuj, but the key anticancer antibody component is amivantamab. Pharmacologically, amivantamab is a bispecific antibody … Read more
Introduction Trametinib is an oral targeted anticancer drug marketed under the brand name Mekinist. Pharmacologically, trametinib belongs to the mitogen-activated extracellular signal-regulated kinase inhibitor class, commonly called MEK inhibitors. MEK1 and MEK2 are important kinases in the RAS-RAF-MEK-ERK signaling pathway. This pathway regulates cell growth, proliferation, survival, differentiation, and migration. In several cancers, mutations in … Read more
Introduction Ponatinib is an oral targeted anticancer drug used in selected Philadelphia chromosome-positive leukemias. It is marketed under the brand name Iclusig. Pharmacologically, ponatinib belongs to the BCR-ABL tyrosine kinase inhibitor class and is often described as a third-generation BCR-ABL inhibitor. Philadelphia chromosome-positive chronic myeloid leukemia, or Ph+ CML, and Philadelphia chromosome-positive acute lymphoblastic leukemia, … Read more
Introduction Nilotinib is an oral anticancer drug used mainly in Philadelphia chromosome-positive chronic myeloid leukemia, commonly abbreviated as Ph+ CML. It belongs to the BCR-ABL tyrosine kinase inhibitor class. The most widely known brand name is Tasigna, and another formulation is Danziten. Nilotinib is pharmacologically related to imatinib but was designed to bind the BCR-ABL … Read more
Introduction Cladribine is a purine nucleoside analogue used as an immunosuppressive and antineoplastic drug. It is available under important brand names such as Mavenclad for relapsing forms of multiple sclerosis and Leustatin for hairy cell leukemia. Pharmacologically, cladribine is an adenosine analogue that is resistant to degradation by adenosine deaminase, allowing it to persist inside … Read more
